Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025Blood

Risk of second primary malignancies among CLL survivors across treatment eras: A SEER-based study with racial and ethnic stratification

View Full Paper
Ask AI
Bookmark
Share

Authors

CSChaitra Surapaneni

Discussion

Loading...

Member takes

Overview

Analysis reveals increased risk of second primary malignancies in CLL survivors, highlighting racial disparities post-targeted treatments.

Key Points

  • To evaluate the risk of second primary malignancies among CLL survivors across different treatment eras and racial/ethnic groups.
  • Analyzed SEER data from 2000-2022
  • Studied patients with Chronic Lymphocytic Leukemia
  • Compared risks of second primary malignancies between pretarget and posttarget treatment eras
  • Categorized outcomes by Race and Ethnicity
  • Increased incidence of second primary malignancies from pretarget era to posttarget era
  • Significant racial disparities persisted in second primary malignancy rates
  • Hodgkin's lymphoma showed the highest risk increase in posttarget treatment era
  • Chronic myeloid leukemia also showed elevated risk
  • Standardized incidence ratios increased across multiple racial/ethnic groups

Cite This Study

Chaitra Surapaneni (2025) studied this question.

synapsesocial.com/papers/693624dd4fa91c937236d1cfhttps://doi.org/10.1182/blood-2025-8025
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Second primary malignancies in patients with chronic lymphocytic leukemia: A SEER analysis, 2000–2022.2026
  2. 2Racial/ethnic disparities in risk of second primary malignancies among Diffuse Large B-cell Lymphoma survivors.2026
  3. 3Racial disparities in risk of second primary malignancies in esophageal cancer survivors: Insights from a population-based database.2026
  4. 4Second primary malignancies in Asian chronic lymphocytic leukaemia patients: A Taiwan Cancer Registry Study2026
  5. 5Risk factors for second primary malignancies (SPM) in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL): A real-world study.2026